Published in Front Oncol on October 07, 2016
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | NCT02239900
Phase 2 Study of MEDI4736 in Patients With Glioblastoma | NCT02336165
SRS (Stereotactic Radiosurgery) Plus Ipilimumab | NCT01950195
Advancing Immune and Cell-Based Therapies Through Imaging. Mol Imaging Biol (2017) 0.75
Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis. EBioMedicine (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Structural and functional features of central nervous system lymphatic vessels. Nature (2015) 8.73
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (2012) 3.56
Regulation of innate immune responses in the brain. Nat Rev Immunol (2009) 3.41
CNS immune privilege: hiding in plain sight. Immunol Rev (2006) 3.13
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One (2011) 2.35
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol (2012) 2.02
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 1.92
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res (2014) 1.73
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem (2011) 1.58
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol (2014) 1.53
Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol (2015) 1.50
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer (2014) 1.48
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol (2014) 1.40
Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res (2010) 1.39
Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys (2010) 1.39
Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep (2002) 1.36
Immune monitoring using the predictive power of immune profiles. J Immunother Cancer (2013) 1.36
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 1.35
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys (2007) 1.28
A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol (2012) 1.24
Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett (2013) 1.24
Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol (2014) 1.21
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys (2015) 1.21
Radiation as an immune modulator. Semin Radiat Oncol (2013) 1.19
The therapeutic potential of microRNAs in cancer. Cancer J (2012) 1.18
Hypoxia potentiates glioma-mediated immunosuppression. PLoS One (2011) 1.17
Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 1.15
Epidemiology of gliomas. Cancer Treat Res (2015) 1.15
Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One (2014) 1.10
Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results. Transl Oncol (2014) 1.08
Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys (2014) 1.08
Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology (2014) 1.03
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology (2014) 0.99
Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer (2013) 0.98
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol (2013) 0.95
Role of Radiation-induced TGF-beta Signaling in Cancer Therapy. Mol Cell Pharmacol (2009) 0.95
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol (2015) 0.89
Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg (2015) 0.88
Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88
Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology (2014) 0.86
Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci (2014) 0.84
Biomarkers for glioma immunotherapy: the next generation. J Neurooncol (2015) 0.78
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Curr Treat Options Oncol (2015) 0.78
Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol (2015) 0.76
Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma. Cancer Immunol Immunother (2015) 0.76